L1CAM and endometrial cancer: The resulting positivity rate of 11% was considerably lower compared to the 17% determined with immunohistochemistry (≥ 10% L1CAM expressing cells) in our multicenter series of 1021 early type 1 endometrial cancers [5] and was closer to the reported positivity rate of 7% revealed for the retrospective analyses obtained from the PORTEC-1 and PORTEC-2 data [6].